Severe COVID-19 ARDS Treated by Bronchoalveolar Lavage with Diluted Exogenous Pulmonary Surfactant as Salvage Therapy: In Pursuit of the Holy Grail?

Barbara Ruaro Paola ConfalonieriRiccardo PozzanStefano TavanoLucrezia MondiniElisa BaratellaAlessandra PagninSelene LerdaPietro GeriMarco BioloMarco Confalonieri Francesco Salton

Published in: Journal of clinical medicine (2022)

Combining the administration of diluted, exogenous pulmonary surfactant via bronchoalveolar lavage along with the standard therapy for SARS-CoV-2-induced ARDS may be a promising way of improving the management of ARDS.

Keyphrases

sars cov
acute respiratory distress syndrome
extracorporeal membrane oxygenation
mechanical ventilation
pulmonary hypertension
respiratory syndrome coronavirus
coronavirus disease
drug induced
high glucose
early onset
intensive care unit
endothelial cells
replacement therapy